In addition, RRM2 have been reported in previous studies as an endogenous ferroptosis inhibitor, which maintains glutathione synthesis by regulating glutathione synthase, thereby exerting an anti-ferroptotic effect in HCC (Yang et al., 2020). The gene discussed is RRM2; the disease is hepatocellular carcinoma.